HLSE:HRTIS

Stock Analysis Report

Executive Summary

Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Herantis Pharma Oyj is covered by less than 3 analysts.

Share Price & News

How has Herantis Pharma Oyj's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.3%

HLSE:HRTIS

-0.9%

FI Pharmaceuticals

-1.4%

FI Market


1 Year Return

-16.5%

HLSE:HRTIS

7.6%

FI Pharmaceuticals

-4.9%

FI Market

HRTIS underperformed the Pharmaceuticals industry which returned 5.7% over the past year.

HRTIS underperformed the Market in Finland which returned -5% over the past year.


Share holder returns

HRTISIndustryMarket
7 Day-3.3%-0.9%-1.4%
30 Day-1.7%2.2%-1.1%
90 Day5.5%10.6%-1.6%
1 Year-16.5%-16.5%12.5%7.6%-0.6%-4.9%
3 Year497.9%497.9%5.5%-7.3%26.4%11.9%
5 Year-36.3%-36.3%38.5%11.3%53.1%24.0%

Price Volatility Vs. Market

How volatile is Herantis Pharma Oyj's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Herantis Pharma Oyj undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Herantis Pharma Oyj is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Herantis Pharma Oyj has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Herantis Pharma Oyj expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Herantis Pharma Oyj is high growth as no revenue estimate data is available.

Herantis Pharma Oyj is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Herantis Pharma Oyj's revenue growth to the Finland market average as no estimate data is available.

Unable to compare Herantis Pharma Oyj's earnings growth to the Finland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Herantis Pharma Oyj's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Herantis Pharma Oyj will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Herantis Pharma Oyj performed over the past 5 years?

16.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Herantis Pharma Oyj does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Herantis Pharma Oyj's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Herantis Pharma Oyj's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Herantis Pharma Oyj has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Herantis Pharma Oyj has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Herantis Pharma Oyj improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Herantis Pharma Oyj's financial position?


Financial Position Analysis

Herantis Pharma Oyj is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Herantis Pharma Oyj's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Herantis Pharma Oyj has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Herantis Pharma Oyj's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Herantis Pharma Oyj has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Herantis Pharma Oyj has less than a year of cash runway based on current free cash flow.

Herantis Pharma Oyj has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.6% each year.


Next Steps

Dividend

What is Herantis Pharma Oyj's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Herantis Pharma Oyj's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Herantis Pharma Oyj's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Herantis Pharma Oyj has not reported any payouts.

Unable to verify if Herantis Pharma Oyj's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Herantis Pharma Oyj has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Herantis Pharma Oyj's dividends in 3 years as they are not expected to pay a notable one for Finland.


Next Steps

Management

What is the CEO of Herantis Pharma Oyj's salary, the management and board of directors tenure and is there insider trading?

7.4yrs

Average management tenure


CEO

Pekka Simula

5.8yrs

Tenure

Mr. Pekka Ilmari Simula, M.Sc. (Tech) has been Chief Executive Officer of Herantis Pharma Oyj since his joining in November 2013 and serves as its Managing Director. Mr. Simula served as the Chief Operatin ...


Management Age and Tenure

7.4yrs

Average Tenure

The average tenure for the Herantis Pharma Oyj management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

5.6yrs

Average Tenure

59yo

Average Age

The tenure for the Herantis Pharma Oyj board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Henri Huttunen

    Chief Scientific Officer

    • Tenure: 9.5yrs
  • Pekka Simula

    CEO & MD

    • Tenure: 5.8yrs
  • Antti Vuolanto

    Chief Operating Officer

    • Tenure: 1.5yrs
  • Jutta Poutanen

    Chief Pharmaceutical Officer

    • Tenure: 9.0yrs
  • Outi Lahdenperä

    Chief Medical Ofcer


Board Members

  • Pekka Allan Mattila

    Chairman of the Board

    • Tenure: 6.6yrs
  • Seppo Kaakkola

    Member of Scientific Advisory Board

  • Kari Alitalo

    Member of Scientific Advisory Board

  • Aki Prihti

    Director

    • Tenure: 5.6yrs
  • Alan Whone

    Member of Scientific Advisory Board

  • Mart Saarma

    Member of Scientific Advisory Board

  • Timo Veromaa (59yo)

    Director

    • Tenure: 7.6yrs
  • Jonathan Kenneth Knowles (72yo)

    Chairman of Scientific Advisory Board

  • Jim Phillips (57yo)

    Director

    • Tenure: 5.6yrs
  • Frans Wuite

    Director

    • Tenure: 5.6yrs

Company Information

Herantis Pharma Oyj's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Herantis Pharma Oyj
  • Ticker: HRTIS
  • Exchange: HLSE
  • Founded: 2008
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: €35.347m
  • Shares outstanding: 6.09m
  • Website: Click here

Number of Employees


Location

  • Herantis Pharma Oyj
  • Bertel Jungin Aukio 1
  • Espoo
  • 2600
  • Finland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HRTISHLSE (OMX Nordic Exchange Helsinki)YesShare CapitalFIEURJun 2014
HRPM.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2014

Biography

Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson’s  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 21:49
End of Day Share Price2019/08/14 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.